Indeed, it has been reported that basal levels of erbB2/erbB3 heterodimers are greatly reduced following treatment of BT-474 breast cancer cells with gefitinib, resulting in a substantial blunting of response to HRGβ1 treatment [47]. Here, ERBB2 is linked to breast carcinoma.